Jeito Capital
Investor profile
Deals
12
distinct rounds
Companies
10
backed
Active span
2020–2025
6 yrs
Total round €
€913M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Forbion5
- SV Health Investors3
- UPMC Enterprises3
- Gilde Healthcare2
- INKEF Capital2
- Invus2
- MRL Ventures Fund2
- Novo Holdings2
- Polaris Partners2
- Samsara Biocapital2
- Sofinnova Partners2
- Syncona Partners2
- Ysios Capital2
- 4BIO Capital1
- ALSA Ventures1
- AXA IM Alts1
- Bain Capital Life Sciences1
- Bayern Kapital1
- BioGeneration Ventures1
- BioGeneration Ventures (BGV)1
- BioMedPartners1
- Bpifrance1
- Brandon Capital1
- British Patient Capital1
- Coparion1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Quell Therapeutics | UK | 1 | €138M |
| Noema Pharma | Switzerland | 2 | €135M |
| Azafaros | Netherlands | 1 | €132M |
| EyeBiotech | UK | 2 | €117M |
| Neogene Therapeutics | Netherlands | 1 | €93M |
| Precirix | Belgium | 1 | €80M |
| Sparingvision | France | 1 | €75M |
| ReproNovo | Switzerland | 1 | €57M |
| CatalYm | Germany | 1 | €50M |
| NMD Pharma | Denmark | 1 | €35M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Quell Therapeutics | Series B | €138M | 2021-11 |
| Azafaros | Series B | €132M | 2025-05 |
| Noema Pharma | Series B | €106M | 2023-03 |
| Neogene Therapeutics | Other | €93M | 2020-09 |
| Precirix | Series B | €80M | 2022-03 |
| Sparingvision | Series B | €75M | 2022-09 |
| EyeBiotech | Series A | €60M | 2023-11 |
| EyeBiotech | Series A | €57M | 2022-02 |
| ReproNovo | Series A | €57M | 2025-05 |
| CatalYm | Series C | €50M | 2022-11 |